| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| License revenue | 784 | 952 | 393 | 547 |
| Selling, general and administrative | - | 1,551 | 1,081 | 1,310 |
| General and administrative | 1,518 | - | - | - |
| Impairment of long-lived assets (note 4) | - | 0 | - | - |
| Write-off of patents and trademarks | 32 | 0 | 88 | - |
| Depreciation and amortization | 96 | 96 | 95 | 96 |
| Total operating expenses | 1,646 | 1,647 | 1,264 | 1,406 |
| Loss from operations | -862 | -695 | -871 | -859 |
| Interest expense and other financing costs | 3 | 2 | 2 | - |
| Sublease income | 534 | 376 | - | - |
| Miscellaneous income | 381 | 866 | 205 | -295 |
| Financing interest expense | - | - | - | 3 |
| Total other income, net | 912 | 1,240 | 203 | 292 |
| Income (loss) from continuing operations before income taxes | 50 | 545 | -668 | -567 |
| Income tax benefit | - | 0 | -32 | - |
| Income (loss) from continuing operations, net of income taxes | 50 | 545 | -636 | -567 |
| Income (loss) from discontinued operations, net of income taxes | 102 | 6 | -17 | -42 |
| Net income (loss) | 152 | 551 | -653 | -609 |
| Net income (loss) per common share, basic (in dollars per share) | 0.01 | 0.05 | -0.06 | -0.05 |
| Net income (loss) per common share, diluted (in dollars per share) | 0.01 | 0.05 | -0.06 | -0.05 |
| Weighted average common shares, basic (in shares) | 11,574,000 | 11,574,000 | 11,552,000 | 11,532,000 |
| Weighted average common shares, diluted (in shares) | 11,574,000 | 11,574,000 | 11,552,000 | 11,532,000 |
TherapeuticsMD, Inc. (TXMD)
TherapeuticsMD, Inc. (TXMD)